Abstract：
OBJECTIVE: Atypical antipsychotics are associated with several adverse effects including metabolic syndrome, weight gain, QTc interval prolongation, and extrapyramidal effects. This study aims to investigate the risk of renal impairment in patients receiving atypical antipsychotics.
METHODS: A systematic literature search was conducted via PubMed and Ovid SP and Web of Science to retrieve studies reporting the risk of renal impairment in patients receiving atypical antipsychotic treatment. The pooled risk ratio (RR) of renal impairment and the subgroup analysis was calculated using the random-effects generic inverse variance method in Cochrane Review Manager.
RESULTS: A total of 4 studies involving 514,710 patients (221, 873 patients on atypical antipsychotics/CKD and 292, 837 controls) were included in this meta-analysis. Patients on atypical antipsychotics exhibited an increased risk of renal impairment, with a pooled risk ratio of 1.34 (95%CI 1.23-1.47). Subgroup analysis demonstrated that atypical antipsychotic use was associated with an increased risk of both acute kidney injury (AKI) (RR 1.51, 95%CI 1.34-1.71) and chronic kidney disease (CKD) (RR: 1.23, 95%CI 1.12-1.35).
CONCLUSIONS: Patients receiving atypical antipsychotics have an increased risk of renal impairment. Quetiapine carries the highest risk of renal impairment encompassing both AKI and CKD.
METHODS: A systematic literature search was conducted via PubMed and Ovid SP and Web of Science to retrieve studies reporting the risk of renal impairment in patients receiving atypical antipsychotic treatment. The pooled risk ratio (RR) of renal impairment and the subgroup analysis was calculated using the random-effects generic inverse variance method in Cochrane Review Manager.
RESULTS: A total of 4 studies involving 514,710 patients (221, 873 patients on atypical antipsychotics/CKD and 292, 837 controls) were included in this meta-analysis. Patients on atypical antipsychotics exhibited an increased risk of renal impairment, with a pooled risk ratio of 1.34 (95%CI 1.23-1.47). Subgroup analysis demonstrated that atypical antipsychotic use was associated with an increased risk of both acute kidney injury (AKI) (RR 1.51, 95%CI 1.34-1.71) and chronic kidney disease (CKD) (RR: 1.23, 95%CI 1.12-1.35).
CONCLUSIONS: Patients receiving atypical antipsychotics have an increased risk of renal impairment. Quetiapine carries the highest risk of renal impairment encompassing both AKI and CKD.
摘要：
目的：非典型抗精神病药物与几种不良反应相关，包括代谢综合征，体重增加,QTc间期延长,和锥体外系效应。这项研究旨在调查接受非典型抗精神病药物的患者发生肾功能损害的风险。
方法：通过PubMed和OvidSP和WebofScience进行了系统的文献检索，以检索报告接受非典型抗精神病药物治疗患者肾损害风险的研究。使用CochraneReviewManager中的随机效应通用逆方差方法计算肾损害和亚组分析的合并风险比（RR）。
结果：本荟萃分析共纳入4项研究，涉及514,710例患者（221,873例非典型抗精神病药/CKD患者和292,837例对照）。使用非典型抗精神病药物的患者出现肾损害的风险增加，合并风险比为1.34（95CI1.23-1.47）。亚组分析表明，使用非典型抗精神病药物与急性肾损伤（AKI）（RR1.51，95CI1.34-1.71）和慢性肾病（CKD）（RR：1.23，95CI1.12-1.35）的风险增加相关。
结论：接受非典型抗精神病药物治疗的患者肾损害风险增加。喹硫平的肾损害风险最高，包括AKI和CKD。
方法：通过PubMed和OvidSP和WebofScience进行了系统的文献检索，以检索报告接受非典型抗精神病药物治疗患者肾损害风险的研究。使用CochraneReviewManager中的随机效应通用逆方差方法计算肾损害和亚组分析的合并风险比（RR）。
结果：本荟萃分析共纳入4项研究，涉及514,710例患者（221,873例非典型抗精神病药/CKD患者和292,837例对照）。使用非典型抗精神病药物的患者出现肾损害的风险增加，合并风险比为1.34（95CI1.23-1.47）。亚组分析表明，使用非典型抗精神病药物与急性肾损伤（AKI）（RR1.51，95CI1.34-1.71）和慢性肾病（CKD）（RR：1.23，95CI1.12-1.35）的风险增加相关。
结论：接受非典型抗精神病药物治疗的患者肾损害风险增加。喹硫平的肾损害风险最高，包括AKI和CKD。
